Skip to main content
  • Bayer Global

To visit the global Xarelto® website, please choose from the options below:

  • I am an HCP

This website is intended to provide informationto an international audience outsie the USA, the UK,
Austria ans Southern African coutries including South Africa. If you are a US visitor, please  click here .

Summary of Product Characteristic
  • Home
  • Indications
    • Stroke Prevention in Non-Valvular Atrial Fibrillation
    • Treatment of PE/DVT and Prevention of Recurrent VTE
    • Prevention of Atherothrombotic Events in Adults with Coronary Artery Disease
    • Secondary Prevention in Events PAD
    • Prevention of Atherothrombotic Events in Chronic PAD
    • Prevention of VTE after Elective Hip Replacement Surgery
    • Prevention of VTE after Elective Knee Replacement Surgery
  • Dosing Guide
  • Practical Management
    • Responsible Use
    • Q&A
  • Prescribing Information
    • Xarelto 2.5 mg
    • Xarelto 10 mg
    • Xarelto 15 mg
  • Resources
    • Useful Websites
  • Country select
    • Brazil
    • Canada
    • Denmark
    • France
    • Germany
    • Hungary
    • Japan
    • Netherlands
    • Norway
    • Spain
    • Sweden
    • Switzerland
    • United Kingdom
    • United States of America
  • English
  • Ukrainian (Ukraine)
  • Bayer Global

Labelings Menu

  • Інструкції для медичного застосування лікарського засобу Ксарелто®
    • Ксарелто®  – 15 мг та 20 мг
    • Ксарелто®  – 2,5 мг
    • Ксарелто® – 10 мг

If you would prefer to visit your local website, please select your country:

To visit the global Xarelto® website, please choose from the options below:

  • I am an HCP

This website is intended to provide informationto an international audience outsie the USA, the UK,
Austria ans Southern African coutries including South Africa. If you are a US visitor, please  click here .

Summary of Product Characteristic
  • Bayer Global
Counter Joe
Counter Grandma portions
Counter Mom
Counter Helping Hands
Counter Grandma treats
Bayer logo
Xarelto logo

Sitemap

  • Home
  • Indications
    • Stroke Prevention in Non-Valvular Atrial Fibrillation
    • Treatment of PE/DVT and Prevention of Recurrent VTE
    • Prevention of Atherothrombotic Events in Adults with Coronary Artery Disease
    • Secondary Prevention in Events PAD
    • Prevention of Atherothrombotic Events in Chronic PAD
    • Prevention of VTE after Elective Hip Replacement Surgery
    • Prevention of VTE after Elective Knee Replacement Surgery
  • Dosing Guide
  • Practical Management
    • Responsible Use
    • Q&A
  • Prescribing Information
    • Xarelto 2.5 mg
    • Xarelto 10 mg
    • Xarelto 15 mg
  • Resources
    • Useful Websites
  • Privacy statement
  • Conditions of use
  • Imprint
  • Sitemap
  • Зв'язатися з нами
  • Report a side effect

© 2020 Bayer AG

This website contains information on Xarelto (rivaroxaban) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK.

Last updated on 12/01/2020
hidden link for autofocus
Cookie consent image